Univariate probabilities of outcomes
| Outcome event . | MSD . | mmRD . | URD . | P . | |||||
|---|---|---|---|---|---|---|---|---|---|
| No. . | Probability (95% CI), % . | No. . | Probability (95% CI), % . | No. . | Probability (95% CI), % . | MSD vs mmRD . | mmRD vs URD . | MSD vs URD . | |
| Acute 2-4 GVHD | 1202 | 151 | 265 | ||||||
| At 100 d | 29 (26-31) | 56 (48-64) | 45 (39-51) | < .001 | .031 | < .001 | |||
| Acute 3-4 GVHD | 1206 | 151 | 266 | ||||||
| At 100 d | 10 (8-11) | 26 (20-34) | 18 (14-23) | < .001 | .051 | < .001 | |||
| Chronic GVHD | 1200 | 147 | 263 | ||||||
| At 1 y | 15 (13-17) | 30 (23-38) | 33 (27-39) | < .001 | .573 | < .001 | |||
| Extensive chronic GVHD | 1203 | 149 | 264 | ||||||
| At 1 y | 6 (5-7) | 13 (8-19) | 21 (17-27) | < .001 | .029 | < .001 | |||
| Relapse | 1197 | 148 | 264 | ||||||
| At 1 y | 27 (24-29) | 20 (14-27) | 25 (20-31) | .054 | .189 | .667 | |||
| At 2 y | 33 (30-36) | 25 (18-33) | 30 (25-36) | .046 | .301 | .331 | |||
| At 3 y | 36 (33-39) | 29 (22-37) | 32 (27-38) | .096 | .524 | .229 | |||
| TRM | 1197 | 148 | 264 | ||||||
| At 1 y | 8 (7-10) | 26 (19-33) | 21 (16-26) | < .001 | .253 | < .001 | |||
| At 2 y | 10 (8-11) | 27 (20-34) | 24 (19-29) | < .001 | .485 | < .001 | |||
| At 3 y | 10 (8-12) | 27 (20-34) | 24 (19-30) | < .001 | .615 | < .001 | |||
| Disease-free survival | 1197 | 148 | 264 | ||||||
| At 1 y | 65 (62-67) | 54 (46-62) | 54 (48-60) | .017 | .914 | .001 | |||
| At 2 y | 57 (54-60) | 48 (40-56) | 46 (40-52) | .041 | .754 | .001 | |||
| At 3 y | 54 (51-57) | 44 (36-53) | 43 (37-49) | .035 | .875 | .002 | |||
| Overall survival | 1208 | 151 | 266 | ||||||
| At 1 y | 75 (73-78) | 57 (49-65) | 61 (55-67) | < .001 | .438 | < .001 | |||
| At 2 y | 65 (62-68) | 51 (43-60) | 54 (48-60) | .014 | .669 | < .001 | |||
| At 3 y | 61 (58-64) | 51 (43-60) | 50 (44-56) | .026 | .806 | .001 | |||
| Outcome event . | MSD . | mmRD . | URD . | P . | |||||
|---|---|---|---|---|---|---|---|---|---|
| No. . | Probability (95% CI), % . | No. . | Probability (95% CI), % . | No. . | Probability (95% CI), % . | MSD vs mmRD . | mmRD vs URD . | MSD vs URD . | |
| Acute 2-4 GVHD | 1202 | 151 | 265 | ||||||
| At 100 d | 29 (26-31) | 56 (48-64) | 45 (39-51) | < .001 | .031 | < .001 | |||
| Acute 3-4 GVHD | 1206 | 151 | 266 | ||||||
| At 100 d | 10 (8-11) | 26 (20-34) | 18 (14-23) | < .001 | .051 | < .001 | |||
| Chronic GVHD | 1200 | 147 | 263 | ||||||
| At 1 y | 15 (13-17) | 30 (23-38) | 33 (27-39) | < .001 | .573 | < .001 | |||
| Extensive chronic GVHD | 1203 | 149 | 264 | ||||||
| At 1 y | 6 (5-7) | 13 (8-19) | 21 (17-27) | < .001 | .029 | < .001 | |||
| Relapse | 1197 | 148 | 264 | ||||||
| At 1 y | 27 (24-29) | 20 (14-27) | 25 (20-31) | .054 | .189 | .667 | |||
| At 2 y | 33 (30-36) | 25 (18-33) | 30 (25-36) | .046 | .301 | .331 | |||
| At 3 y | 36 (33-39) | 29 (22-37) | 32 (27-38) | .096 | .524 | .229 | |||
| TRM | 1197 | 148 | 264 | ||||||
| At 1 y | 8 (7-10) | 26 (19-33) | 21 (16-26) | < .001 | .253 | < .001 | |||
| At 2 y | 10 (8-11) | 27 (20-34) | 24 (19-29) | < .001 | .485 | < .001 | |||
| At 3 y | 10 (8-12) | 27 (20-34) | 24 (19-30) | < .001 | .615 | < .001 | |||
| Disease-free survival | 1197 | 148 | 264 | ||||||
| At 1 y | 65 (62-67) | 54 (46-62) | 54 (48-60) | .017 | .914 | .001 | |||
| At 2 y | 57 (54-60) | 48 (40-56) | 46 (40-52) | .041 | .754 | .001 | |||
| At 3 y | 54 (51-57) | 44 (36-53) | 43 (37-49) | .035 | .875 | .002 | |||
| Overall survival | 1208 | 151 | 266 | ||||||
| At 1 y | 75 (73-78) | 57 (49-65) | 61 (55-67) | < .001 | .438 | < .001 | |||
| At 2 y | 65 (62-68) | 51 (43-60) | 54 (48-60) | .014 | .669 | < .001 | |||
| At 3 y | 61 (58-64) | 51 (43-60) | 50 (44-56) | .026 | .806 | .001 | |||
MSD indicates matched sibling donor transplant; mmRD, 1-antigen mismatch related donor/phenotypically matched donor transplant; URD, 8/8 matched unrelated donor transplant; CI, confidence interval; GVHD, graft-versus-host disease; and TRM, treatment-related mortality.
Probabilities of acute, chronic GVHD, TRM, and relapse were calculated with the cumulative incidence estimate. Overall survival and disease-free survival were calculated with the Kaplan-Meier product limit estimate.